BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Invokana (Canagliflozin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Invokana (Canagliflozin)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05427084-307@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Invokana (Canagliflozin): Phase 2/3 readout est. (NCT05427084)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2/3\, Type 2 Diabetes.\nStudy:
  Canagliflozin Targeting Vascular Inflammation\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ca
 nagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05427084
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05507892-307@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Invokana (Canagliflozin): Phase 2 readout est. (NCT05507892)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2\, Type 2 Diabetes.\nStudy: R
 enal Mechanism of SGLT2 Inhibition\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/canaglifloz
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5507892
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527390-307@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Invokana (Canagliflozin): Phase 4 readout est. (NCT07527390)
DESCRIPTION:Invokana (Canagliflozin)\, phase 4\, Chronic Kidney Disease.\nS
 tudy: CANagliflozin In DIALysis Patients\nEstimated primary completion: 30
  January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/canagl
 iflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07527390
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06528405-307@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Invokana (Canagliflozin): Phase 2 readout est. (NCT06528405)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2.\nStudy: The Efficacy and Sa
 fety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute K
 idney Disease\nEstimated primary completion: July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/canagliflozin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06528405
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05090358-307@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271008
DTEND;VALUE=DATE:20271009
SUMMARY:Invokana (Canagliflozin): Phase 2 readout est. (NCT05090358)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2.\nStudy: Preventing High Blo
 od Sugar in People Being Treated for Metastatic Breast Cancer\nEstimated p
 rimary completion: 8 October 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/canagliflozin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05090358
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858436-307@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Invokana (Canagliflozin): Phase 4 readout est. (NCT06858436)
DESCRIPTION:Invokana (Canagliflozin)\, phase 4.\nStudy: SGLT2 Inhibitor Uti
 lization Re-perfusion Therapy\nEstimated primary completion: 31 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/canagliflozin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0685843
 6
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06913647-307@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Invokana (Canagliflozin): Phase 2 readout est. (NCT06913647)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2\, Chronic Kidney Disease.\nS
 tudy: Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on
  Peritoneal Dialysis\nEstimated primary completion: 28 February 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/canagliflozin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06913647
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06182839-307@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Invokana (Canagliflozin): Phase 2 readout est. (NCT06182839)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2\, Chronic Kidney Disease.\nS
 tudy: Canagliflozin in Advanced Renal Disease With MRI Endpoints\nEstimate
 d primary completion: 30 March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/canagliflozin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06182839
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07703163-307@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Invokana (Canagliflozin): Phase 1 readout est. (NCT07703163)
DESCRIPTION:Invokana (Canagliflozin)\, phase 1.\nStudy: Safety and Efficacy
  of Canagliflozin in Patients With Locally Advanced or Advanced Solid Canc
 er\nEstimated primary completion: 31 July 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/canagliflozin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07703163
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890064-307@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Invokana (Canagliflozin): Phase 2 readout est. (NCT07890064)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2.\nStudy: Canagliflozin Plus 
 Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial
  Cancer\nEstimated primary completion: 1 January 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/canagliflozin#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07890064
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07547878-307@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Invokana (Canagliflozin): Phase 4 readout est. (NCT07547878)
DESCRIPTION:Invokana (Canagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: R
 apid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies 
 (RAPID-CKD)\nEstimated primary completion: 31 March 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/canagliflozin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07547878
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
